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Metastasis of cancer cells is believed to be influenced by many
factors which progress through several stages as cancer cells move
from a primary lesion to metastatic sites. One of those factors, cell
motility, plays an important role in the progression, especially after
the extravasation. Motility-related protein 1 (MRP-1/CD9), which
belongs to the transmembrane 4 superfamily of membrane proteins,
is considered to inhibit cell motility (Miyake et al, 1991). It has
been demonstrated that the cells which expressed MRP-1/CD9 by
transfection showed suppressed cell motility in vitro (Ikeyama et al,
1993). An inverse correlation was found between MRP-1/CD9
expression and metastases in breast cancer (Miyake et al, 1995),
and reduced MRP-1/CD9 gene expressions resulted in poor prog-
noses in non-small cell lung cancer (Higashiyama et al, 1995).
KAI1/CD82 is also one of the transmembrane 4 superfamily of
membrane proteins which has similar effects, mediating metastasis
and correlating positively with good prognosis in patients with non-
small cell lung cancer (Adachi et al, 1996) and inversely with
metastasis in prostatic cancers (Dong et al, 1995; Dong, 1996).
There were no studies of MRP-1/CD9 and KAI1/CD82 in
oesophageal cancer. In this paper, we investigated expressions of
MRP-1/CD9 and KAI1/CD82 in oesophageal cancer.
MATERIALS AND METHODS
Clinical materials
Tissues, whose expressions of MRP-1/CD9 and KAI1/CD82 were
examined, were obtained from oesophageal cancer specimens of 108
and 104 patients, respectively, who underwent oesophagectomy at
our institution, from June 1987 to December 1995. The operative
techniques were as previously described (Imamura et al, 1987).
Some samples were not available to conduct immunohistochemical
staining, therefore the number of the cases examined in MRP-1/CD9
and KAI1/CD82 was not identical. All resected tumours were micro-
scopically examined to identify histologic type, extent and mode of
cancer invasion, and metastasis to lymph nodes. In some cases
lymphatic invasion could be seen in the apparent absence of lymph
node metastases. Considering this, we investigated the correlation
between the expression of MRP-1/CD9 and lymphatic invasion in 98
out of 108 patients. Nine patients were excluded because lymphatic
invasion could not be conclusively determined.
Histologically, all of the patients had squamous cell carcinoma.
No adenosquamous carcinoma or small cell variants were found.
Tumour staging was based on the pTNM pathological classifica-
tion system (Hermanek et al, 1987). The 5-year survival rates of all
patients who received curative resections were examined.
Specimens were fixed in a 10% formaldehyde solution and
embedded in paraffin. Four-micrometre sections were cut and
mounted on glass slides.
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Summary Although the mechanisms of action of the transmembrane superfamilies, motility-related protein-1 (MRP-1/CD9) and KAI1/CD82,
are not well known, they are reported to suppress the metastasis of several kinds of cancers. The suppression of cell motility by MRP-1/CD9
may cause suppression of the metastasis. As we could not find any reports concerning the expression of MRP-1/CD9 and KAI1/CD82 in
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against 104 cases using anti-KAI1/CD82 monoclonal antibody C33. To investigate the gradual expression of MRP-1/CD9 and KAI1/CD82, 24
oesophageal dysplasias were immunohistochemically stained using the same method and then investigated.
The expression of both MRP-1/CD9 and KAI1/CD82 were positive on the cell membranes of normal oesophageal epithelial cells, but
reduced or negative in the cancer cells. Reduced MRP-1/CD9 expressions significantly correlated to tumour depth (P = 0.0009). We found a
significantly greater number of reduced or negative expression of MRP-1/CD9 and KAI1/CD82 in lymph node metastatic cases (P = 0.0003
and P = 0.0129, respectively), but not in distant metastatic cases. The 5-year survival rate of MRP-1/CD9-negative and reduced patients was
significantly worse than those of positive patients (n = 108, curative cases, RO). Few cases remained KAI1/CD82-positive (9.6%; 10/104) in
oesophageal cancer. Twenty (83.3%) and twenty-two (91.7%) cases out of 24 dysplasias were defined as KAI1/CD82-positive and MRP-
1/CD9-positive, respectively. The decrease in MRP-1/CD9 and KAI1/CD82 expression may facilitate lymph node metastasis in oesophageal
squamous cell carcinomas. Knowing the status of the expression of MRP-1/CD9 appears helpful in predicting the prognosis for each patient.
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Immunohistochemical staining and evaluation
Immunohistochemical staining was performed using the avidin—
biotin method. Tissue sections were deparaffinized and rehydrated in
water. Endogenous peroxidase was blocked with 0.3% hydrogen
peroxide for 30 min. Sections were rehydrated and washed with
phosphate-buffered saline (PBS). Slides were then placed in plastic
Coplin jars containing 10% sodium citrate. Jars were heated in the
microwave oven five times for 3 min each time. After heating, the
jars were removed from the oven and allowed to cool for 20 min.
After the slides were rinsed in PBS three times for 5 min, they were
incubated with 1.5% normal horse serum in PBS for 30 min at room
temperature to block non-specific antibody reaction. Sections were
incubated overnight at 4°C with anti-MRP-1/CD9 monoclonal
antibody M31-15 (Miyake et al, 1995) at a dilution of 1:20 in PBS
containing 1% bovine serum albumin. After six rinses in PBS,
sections were incubated for 40 min at room temperature with
biotinylated anti-mouse immunoglobulin G, followed by six washes
with PBS, and then reacted with an avidin—biotin system, using
0.03% 3,3¢-diaminobenzide tetrahydrochloride for about 4 min as
chromogen. Sections were counterstained with Mayer￿s haema-
toxylin. Negative controls were prepared by substituting normal
mouse IgG for the primary antibody, and resulted in no detectable
staining. In the case of KAI1/CD82 the immunostaining was
conducted using the same methodology as stated above, with the
exception that there was no antigen retrieval method by microwave
oven. The antibody M31—15 was substituted with C33, a monoclonal
antibody for KAI1/CD82 (Ueda et al, 1996) at a dilution of 1:100 in
PBS containing 1% bovine serum albumin.
When more than 50% of the carcinoma cells in a given spec-
imen were positively stained, the sample was classified as MRP-
1/CD9-positive (+); when 5—50% were stained, as MRP-1/
CD9-reduced (±); and when less than 5% were stained, as negative
(—) (Miyake et al, 1995). When more than 10% of the carcinoma
cells in a given specimen were positively stained, the sample was
classified as KAI1/CD82-positive (+); and when less than 10%
were stained, as KAI1/CD82-negative (—).
Statistical analysis
Statistical analysis was performed with c2 analysis and Fisher￿s
exact test. Survival curves of the patients were calculated by
Kaplan—Meier method and analysis was done by log-rank test.
RESULTS
The expression of both MRP-1/CD9 and KAI1/CD82 appeared as
positive on the cell membranes of the normal oesophageal epithe-
lial cells (Figure 1A, MRP-1/CD9; Figure 1B, KAI1/CD82), and
A
B
A
B
Figure 1 (A, B) The immunohistochemical stainings of MRP-1/CD9 and
KAI1/CD82 on oesophageal epithelium using antibody M31-15 and C33,
respectively. Both molecules were detected positively by staining on normal
oesophageal epithelial cellular membranes (magnification: 1A, ´ 200; 1B, ´
200)
Figure 2 (A, B) The immunohistochemical stainings of MRP-1/CD9 and
KAI1/CD82 with the same methods on oesophageal squamous cell
carcinoma. Neither molecule was detected on either cellular membrane or
cytoplasma on carcinoma cells. Normal epithelial cellular membranes were
stained as positive in Figure 2B. These stainings were defined as negative
(magnification: 2A, ´ 200; 2B, ´ 200)1170 S Uchida et al
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Table 1 Characteristics of 108 patients and correlation between the expression of MRP-1/CD9 and clinical classification
Age (years) 43 ~ 84
(Mean age) 64
Result of immunostaining
No. of patients (%)
MRP-1 (–) MRP-1 (±) MRP-1 (+) Total P-value
Sex (no. of patients)
Male 54 20 15 89
Female 12 3 4 19 P = 0.7784
TNM clinical classification
T – Primary tumour
Tis 0 (0) 1 (33.3) 2 (66.7) 3
T1 10 (37.0) 6 (22.2) 11 (40.7) 27
T2 17 (65.4) 4 (15.4) 5 (19.2) 26
T3 26 (74.3) 8 (22.9) 1 (2.9) 35
T4 13 (76.5) 4 (23.5) 0 (0) 17 P = 0.0009
N – Regional lymph nodes
N0 20 (48.8) 6 (14.6) 15 (36.6) 41
N1 46 (68.7) 17 (25.4) 4 (6.0) 67 P = 0.0003
M – Distant metastasis
M0 53 (61.6) 17 (19.8) 16 (18.6) 86
M1 13 (59.1) 6 (27.3) 3 (13.6) 22 P = 0.6950
Stage
Stage 0 0 (0) 1 (33.3) 2 (66.7) 3
Stage I 8 (44.4) 1 (5.6) 9 (50.0) 18
Stage IIA 7 (50.0) 4 (28.6) 3 (21.4) 14
Stage IIB 14 (77.8) 3 (16.7) 1 (5.6) 18
Stage III 24 (72.7) 8 (24.2) 1 (3.0) 33
Stage IV 13 (59.1) 6 (27.3) 3 (13.6) 22 P = 0.0015
Classification method is from TNM Clinical Classification of the Oesophagus 4th edn (1987).
Table 2 Correlation between the expression of MRP-1/CD9 and lymph node metastasis and lymphatic invasion
Result of immunostaining
No. of patients (%)
MRP-1 (–) MRP-1 (±) MRP-1 (+) Total P-value
N – Regional lymph nodes
N0 19 (51.4) 6 (16.2) 12 (32.4) 37
N1 43 (70.5) 14 (23.0) 4 (6.6) 61 P = 0.0035
Lymphatic invasion
ly0 17 (53.1) 5 (15.6) 10 (31.3) 32
ly1 45 (68.2) 15 (22.7) 6 (9.1) 66 P = 0.0204
N0, no regional lymph node metastasis; N1, regional lymph node metastasis; ly 0, no lymphatic invasions; ly 1, lymphatic invasions.
Table 3 Correlation between lymph node metastasis and lymphatic invasion in the same 98 patients
N-Regional lymph nodes
No. of patients
N0 N1 Total P-value
lymphatic invasion
ly0 20 12 32
ly1 17 49 66 P = 0.004
ly0, no lymphatic invasions; ly 1, lymphatic invasions.The expression of MRP-1/CD9 and KAI1/CD82 on oesophageal squamous cell carcinoma 1171
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reduced on the membrane of the cancer cells (Figure 2A, MRP-
1/CD9; Figure 2B, KAI1/CD82).
The number of reduced MRP-1/CD9 expressions significantly
increased as tumours grew deeper (P = 0.0009). We found a signif-
icant inverse correlation between MRP-1/CD9 expression and
lymph node metastasis (P = 0.0003), but not between MRP-1/CD9
expression and distant metastasis. Reduced expression of MRP-
1/CD9 increased as the stage advanced (Table 1). In the 98 patients
investigated, we found significant inverse correlation between
MRP-1/CD9 expression and lymphatic invasion (P = 0.0204). In
these same 98 patients the inverse correlation between MRP-
1/CD9 expression and lymph node metastases was also confirmed
(P = 0.0035) (Table 2). Correspondingly, the lymph node metas-
tases correlated to lymphatic invasion (P = 0.004) (Table 3).
The survival rates of 108 patients who received curative resec-
tion (R0) were examined. (Seventeen stage IV patients did not
have organ metastasis except for cervical lymph nodal metastases,
which were resected.) The 5-year survival rates of MRP-1/CD9-
negative and MRP-1/CD9-reduced patients were significantly
worse than those of MRP-1/CD9-positive patients (Figure 3).
The expression of KAI1/CD82 was also inversely correlated to
lymph node metastasis, but not to distant metastasis (Table 4). Few
cases stained KAI1/CD82-positive (9.6%; 10/104) in oesophageal
cancer, therefore, we examined oesophageal dysplasias to investi-
gate whether KAI1/CD82 expression was preserved in them. We
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Figure 3 The relation between the influence of MRP-1/CD9 and survival
rates. Survival curves of the patients were calculated by Kaplan–Meier
method. The 5-year survival rates of MRP-1/CD9-negative and MRP-1/CD9-
reduced patients showed significantly worse prognoses than that of positive
patients (n = 108, curative cases). alog-rank test
Table 4 Characteristics of 104 patients and correlation between the expression of KAI1/CD82 and clinical classification
Age (years) 43 ~ 84
(Mean age) 64
Result of immunostaining
No. of patients (%)
KAI1 (–) KAI1 (+) Total P-value
Sex (no. of patients)
Male 75 10 85
Female 19 0 19 P = 0.2018*
TNM clinical classification
T – Primary tumour
Tis 3 (42.9) 4 (57.1) 7
T1 23 (88.5) 3 (11.5) 26
T2 24 (96.0) 1 (4.0) 25
T3 29 (96.7) 1 (3.3) 30
T4 15 (93.8) 1 (6.2) 16 P = 0.0003
N – Regional lymph nodes
N0 33 (80.5) 8 (19.5) 41
N1 61 (96.8) 2 (3.2) 63 P = 0.0129*
M – Distant metastasis
M0 77 (90.6) 8 (9.4) 85
M1 19 (100) 0 (0) 19 P > 0.9999*
Stage
Stage 0 3 (42.9) 4 (57.1) 7
Stage I 14 (82.4) 3 (17.6) 17
Stage IIA 11 (91.7) 1 (8.3) 12
Stage IIB 18 (100) 0 (0) 18
Stage III 31 (100) 0 (0) 33
Stage IV 17 (89.5) 2 (10.5) 19 P = 0.0002
Classification method is from TNM Clinical Classification of the Oesophagus, 4th Edn (1987). *Fisher’s exact test.examined 24 dysplastic lesions which were taken from biopsied
preoperative samples. Out of 24 dysplasias examined using the
same immunohistochemical method, 20 (83.3%) cases of the
dysplasia were defined as KAI1/CD82-positive. We then conducted
immunohistochemical staining of MRP-1/CD9 on the same
dysplasias, and 22 (91.7%) were defined as MRP-1/CD9-positive.
DISCUSSION
We have shown that reduced expression of both transmenbrane
proteins, MRP-1/CD9 and KAI1/CD82, appear to be correlated to
lymph node metastasis in oesophageal cancer patients. As there are
very few reports concerning MRP-1/CD9 or KAI1/CD82 expres-
sions in intestinal tumours or oesophageal cancer, we compared our
study with those on other cancers. MRP-1/CD9 was reported to
reduce its expression in proportion to the state of lymph node metas-
tasis in non-small cell lung cancer (Higashiyama et al, 1995), breast
cancer (Miyake et al, 1995) and colon cancer (Cajot et al, 1997).
Reduced KAI1/CD82 expression was reported to be correlated with
lymph node metastasis and poor prognoses in non-small cell lung
cancer, especially in adenocarcinoma but not in squamous cell carci-
noma (Adachi et al 1996). We found compatible results indicating
reduced expression of both MRP-1/CD9 and KAI1/CD82 correlated
to lymph node metastasis in oesophageal squamous cell carcinoma.
We could not, however, find an inverse correlation in distant
metastatic cases. In these cases, almost all patients￿ distant metas-
tases were cervical lymph node metastases. Finding that
MRP-1/CD9 expression was inversely correlated to lymphatic inva-
sion may suggest that this molecular loss might affect mainly the
closest sites to the primary lesions and thus lead to the local lymph
node metastases. Distant lymph node metastasis may require other
changes.
Reduced expression also correlated to poor prognoses in the
MRP-1/CD9 expression in oesophageal carcinoma, as they had in
other carcinomas. As most of the oesophageal carcinoma showed
reduced expressions of KAI1/CD82, the correlation between
KAI1/CD82 expressions and prognoses is not presented here.
Although the mechanism of the inhibitory effect on metastasis
of these two transmembrane proteins has not been examined
extensively, the inhibitory effect on metastasis by MRP-1/CD9 is
believed to be due to suppression of cell motility. MRP-1/CD9 was
also reported to interact with heparin-binding epidermal growth
factor (EGF)-like growth factor associated with a3b1 integrin
(Higashiyama et al, 1995; Nakamura et al, 1995). These adhe-
sional effects may play an essential role in the initiation of a
metastatic cascade. The antibody to MRP-1/CD9 was reported to
aggregate platelets and activate their function (Hato et al, 1988;
Higashihara et al, 1990). Platelets may release several growth
factors which may facilitate tumour activation or growth.
We found a larger decrease in expression of KAI1/CD82
compared to MRP-1/CD9 in oesophageal cancer. Perhaps because of
the specific nature of each antibody, the expression of KAI1/CD82 is
thought to disappear at an earlier stage in carcinogenesis than MRP-
1/CD9. Expression of both KAI1/CD82 and MRP-1/CD9 was
preserved in many cases of dysplasia. The characteristic difference
between the KAI1/CD82 and MRP-1/CD9 molecules may appear
after dysplastic degradation in the oesophageal tumorigenesis.
KAI1/CD82 has a larger molecular weight, 29.610 kDa, than
MRP-1/CD9, 24.28 kDa. Structurally, KAI1/CD82 has three N-
glycosylation sites, while MRP-1/CD9 has one site (Boucheix C et
al, 1991; Dong et al, 1995). It is thought that N-glycosylation sites
play an important role in the suppression of metastasis (Hakomori
et al, 1989), but it is not well known what role these differences
play. Though there were some differences between them, their
basic characteristics seemed to resemble each other. Their expres-
sion disappeared in oesophageal cancer and loss of that expression
seemed to correlate with the ability to initiate metastasis.
Preserving those molecules might prevent the patient from metas-
tases and knowledge of the level of expression may become a
useful predictor of prognoses for oesophageal cancer patients.
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